Novartis Ag (NVS) Tax Provisions (2009 - 2026)

Novartis Ag has disclosed Tax Provisions across 18 years of filings, most recently posting -$1.0 billion for Q2 2026.

• In Q2 2026, Tax Provisions fell 99.61% year-over-year to -$1.0 billion; the TTM figure through Jun 2026 stood at -$3.3 billion (down 19.15% YoY), while the FY2025 annual figure was -$2.4 billion, down 40.21% from the prior year.
• Tax Provisions came in at -$1.0 billion for Q2 2026 at Novartis Ag, down from -$683.0 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of -$39.0 million in Q3 2023 to a low of -$1.3 billion in Q4 2025.
• Average Tax Provisions over 5 years is -$588.6 million, with a median of -$478.5 million recorded in 2022.
• Year-over-year, Tax Provisions soared 84.82% in 2023 and slumped 412.82% in 2024.
• Over 5 years, Tax Provisions stood at -$874.0 million in 2022, then advanced by 7.09% to -$812.0 million in 2023, then tumbled by 52.22% to -$1.2 billion in 2024, then slipped by 5.58% to -$1.3 billion in 2025, then advanced by 22.45% to -$1.0 billion in 2026.
• Per Business Quant data, the three most recent Tax Provisions figures were -$1.0 billion in Q2 2026, -$683.0 million in Q1 2026, and -$1.3 billion in Q4 2025.